Insider Stock Trading History of Camber Capital Management Llc


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Camber Capital Management Llc since year 2005. The trader's CIK number is 1444043. At the time of this reporting, Camber Capital Management Llc is the 10% Owner of Protalix Biotherapeutics, Inc. . (stock ticker symbol PLX). See this page for all insider trading activities at Protalix Biotherapeutics, Inc. .

Note that in the past Camber Capital Management LLC also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Camber Capital Management Llc since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2016-12-02 PLX Protalix Biotherapeutics, Inc. Sale 2,500,000 .32 792,500
2016-12-02 PLX Protalix Biotherapeutics, Inc. Sale 2,500,000 .32 792,500
2016-09-19 CSII Replidyne Inc Sale 1,043,000 23.25 24,249,750
2016-09-20 CSII Replidyne Inc Sale 57,000 23.54 1,341,666
2015-12-30 SQNM Sequenom Inc Buy 195,000 1.59 310,635
2016-01-04 SQNM Sequenom Inc Buy 75,000 1.59 119,250
2015-12-31 SQNM Sequenom Inc Buy 395,435 1.64 648,513
2015-12-14 SQNM Sequenom Inc Buy 448,000 1.28 573,440
2015-12-15 SQNM Sequenom Inc Buy 20,000 1.41 28,180
2015-12-08 SQNM Sequenom Inc Buy 325,000 1.24 401,375
2015-12-09 SQNM Sequenom Inc Buy 213,000 1.32 281,586
2015-12-10 SQNM Sequenom Inc Buy 253,565 1.36 344,087
2015-10-19 PLX Protalix Biotherapeutics, Inc. Buy 4,000,423 1.01 4,060,429
2015-10-06 SQNM Sequenom Inc Buy 925,044 1.90 1,753,883
2015-10-07 SQNM Sequenom Inc Buy 162,718 1.98 322,344
2015-10-08 SQNM Sequenom Inc Buy 562,328 2.07 1,161,769
2012-08-02 WHRT World Heart Corp Sale 1,639,345 89.79 147,196,787

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Camber Capital Management Llc (10% Owner of Protalix Biotherapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.